CytomX FY2023 revenue $101.2M, operating expenses down 30%; BMS discontinues 986288, CX-904 data H2 2024

CytomX Therapeutics, Inc.

FY2023 revenue $101.2M (up from $53.2M in 2022); operating expenses $107.7M (down from $154.5M).
Cash $174.5M at Dec 31, 2023 vs $193.7M a year earlier; includes $30M from July 2023 BVF financing.
BMS notified CytomX it will not continue BMS-986288 beyond current Phase 2; research collaboration with multiple TCE programs continues.
CX-904 EGFRxCD3 Phase 1a data expected H2 2024; CX-2051 and CX-801 Phase 1 starts H1 2024 after IND clearance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CytomX Therapeutics, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 11, 2024, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-029207

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.